



Accredited by
Joint Commission International

A. K. SINGHAL

Vice President
Cum Company Secretary

Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



Ref.: IMCL/CS/NSE/BM/2017

28th July, 2017

The National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Bandra-kurla Complex,
Bandra (E)
Mumbai - 400 051

Stock Code INDRAMEDCO

Sub.: Unaudited Financial Results for the quarter ended 30th June, 2017

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter ended 30th June, 2017, along with a copy of the Limited Review Report by the Auditors.

The Board meeting ended at 2.20 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,


A.K.SINGHAL

Encl. as above

Statement of Unaudited Financial Results for the Quarter ended 30th June, 2017

Amount (Rs. in Lacs)

S. No.	Particulars	Quarter ended			Financial Year ended
		30.06.2017 (Unaudited)	31.03.2017 (Audited)	30.06.2016 (Unaudited)	31.03.2017 (Audited)
1	Revenue from operations	18423.51	18739.99	19353.02	76571.62
2	Other Income	8.70	123.56	7.38	159.26
3	Total income	18432.21	18863.55	19360.40	76730.88
4	Expenses				
	a) Cost of material consumed	3589.42	3665.25	3812.53	15021.28
	b) Purchase of stock in trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	d) Employee benefits expense	4623.61	4866.36	4661.54	19025.71
	e) Consultation fee paid to Doctors	4795.92	4612.32	4919.81	19145.51
	f) Finance cost	212.21	221.75	170.19	790.54
	g) Depreciation and amortisation expense	758.80	826.21	731.04	3053.21
	h) Other expenses	3723.79	3926.70	3820.15	15612.87
	Total expenses	17703.75	18118.59	18115.26	72649.12
5	Profit before exceptional items and tax	728.46	744.96	1245.14	4081.76
6	Exceptional items	-	-	-	-
7	Profit before tax (PBT)	728.46	744.96	1245.14	4081.76
8	Tax expense				
	Current tax	315.56	471.81	469.37	1854.11
	Deferred tax	(63.05)	(194.85)	(42.69)	(396.88)
9	Profit for the period after tax (PAT)	475.95	468.00	818.46	2624.53
10	Other comprehensive income				
	a). (i) Items that will not be reclassified to profit or loss	7.43	65.56	22.13	106.14
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(2.57)	(22.69)	(7.66)	(36.73)
	Total other comprehensive income, Net of tax expenses	4.86	42.87	14.47	69.41
11	Total comprehensive income for the period	480.81	510.87	832.93	2693.94
12	Paid-up equity share capital (Face value Rs. 10/- each)	9167.30	9167.30	9167.30	9167.30
13	Earnings per share Basic and Diluted (Rs.)	0.52	0.51	0.89	2.86

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 28th July, 2017.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Statutory Auditors have carried out a Limited review of the financial results for the quarter ending 30th June, 2017.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 28th July, 2017


Jaideep Gupta
Managing Director

Review Report

To
The Board of Directors,
Indraprastha Medical Corporation Limited
New Delhi

Introduction

We have reviewed the accompanying statement of unaudited financial results and the accompanying notes of Indraprastha Medical Corporation Limited ("the Company") for the Quarter ended 30th June 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62 / 2016 dated 5th July 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Other Offices

New Delhi

D-62, Panchsheel Enclave, New Delhi - 110017
Tel: +91-11- 26497629 / 30 Fax: +91-11-41749444

C-20, Panchsheel Enclave, New Delhi -110017
Tel: +91-11-41200800

Ludhiana

B-XIX-220, Rani Jhansi Road,
Near SBI Treasury Branch, Ghumar Mandi,
Ludhiana-141001, (Punjab)
Tel: +91-161-2774527 Fax: +91-161-2771618

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.C. VASUDEVA & CO
Chartered Accountants
FRN-000235-N

Abhinav Khosla
Abhinav Khosla
Partner

M. No. 087010

Place: New Delhi

Date: *28/7/2017.*

